Tadocizumab (YM-337; C4G1) dose-dependently inhibits ex vivo platelet aggregation, with complete inhibition at doses higher than 0.25 mg/kg intravenous injection or 1.5 μg/kg/min infusion in rhesus monkeys[1].
Tadocizumab (YM-337; C4G1) at a dose of 1 mg/kg intravenous injection followed by 6 μg/kg/min infusion for 60 min prevented occlusive thrombus formation in monkeys, in a photochemically-induced thrombosis model in squirrel monkeys[1].
